SCHEMBL22873293

SCHEMBL22873293

CCc1ccc(N2CCC(C(C)C)CC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
L3MBTL1 Q9Y468 8/20 0.41
L3MBTL3 Q96JM7 6/20 0.41
MAPT P10636 4/20 0.40
ALDH1A1 P00352 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
GAA P10253 2/20 0.40
HTT P42858 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
HSP90AA1 P07900 1/20 0.40
HSP90AB1 P08238 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
ALOX12 P18054 1/20 0.40
MAPK1 P28482 1/20 0.40
GFER P55789 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25829684 0.83 KDM4E (0.45) KDM4ENPC1RAB9AL3MBTL1L3MBTL3
SCHEMBL22537523 0.81 USP2 (0.54) KDM4ENPC1RAB9AL3MBTL1L3MBTL3
SCHEMBL24974232 0.81 ADRB1 (0.50) KDM4ENPC1RAB9AL3MBTL1L3MBTL3
SCHEMBL12127989 0.81 KDM4E (0.41) KDM4ENPC1RAB9AL3MBTL1L3MBTL3
SCHEMBL28758087 0.80 KDM4E (0.61) KDM4ENPC1RAB9AL3MBTL1MAPT
SCHEMBL23844438 0.80 L3MBTL3 (0.46) L3MBTL1L3MBTL3ACHEMBTD1TP53BP1
SCHEMBL21431157 0.80 MAPT (0.53) KDM4ENPC1RAB9AL3MBTL1L3MBTL3
SCHEMBL22144419 0.80 KDM4E (0.49) KDM4ENPC1RAB9AL3MBTL1L3MBTL3
SCHEMBL10118804 0.80 HRH3 (0.49) KDM4EL3MBTL1L3MBTL3MAPTALDH1A1
SCHEMBL12988745 0.80 MAPT (0.48) KDM4ENPC1RAB9AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230331681-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2023-10-19 US disclosed
US-11236051-B2 Compounds and methods for the targeted degradation of androgen receptor ARVINAS OPERATIONS, INC. (US) 2022-02-01 US disclosed
US-20210009528-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR Arvinas, Inc. 2021-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331681-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN KDM4E 706/4885NPC1 2673/4885RAB9A 4332/4885
US-20210009528-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN KDM4E 706/4885NPC1 2673/4885RAB9A 4332/4885
US-11236051-B2 Compounds and methods for the targeted degradation of androgen receptor AR, ADRM1, CRBN KDM4E 706/4885NPC1 2673/4885RAB9A 4332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.